Acrux Limited has released a press release.
Acrux has received $1.977m RDTI rebate for FY26
Earlier from Acrux
- FY26 Annual Report and Appendix 4E
- Investor Presentation - Female Testosterone for HSDD
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Acrux licenses Lenzetto for Australian market for AUD5.4m